Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Blood Transfusion and Agglutination

Blood Transfusion and Agglutination

Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...

Immunodeficiency Diseases

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency disorders...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Outcomes of patients with chronic lymphocytic leukemia discontinuing covalent Bruton tyrosine kinase inhibitors due to adverse events.

Leukemia·2026

Same author

Modeled Aqueous Humor Protein Concentrations to Enable Biomarker Development in Uveal Melanoma.

International journal of molecular sciences·2026

Same author

Prospective implementation of an aqueous humor liquid biopsy platform informs clinical diagnosis and management of retinoblastoma and other intraocular lesions.

NPJ precision oncology·2026

Same author

Quality and Readability of Patient Educational Materials Generated by ChatGPT-4o for Pediatric Ophthalmologic Surgeries.

Journal of pediatric ophthalmology and strabismus·2025

Same author

New View of the Milky Way.

Scientific American·2024

Same author

Artificial Intelligence to Differentiate Pediatric Pseudopapilledema and True Papilledema on Fundus Photographs.

Ophthalmology science·2024

Search research articles

Related Experiment Video

Updated: Jul 17, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Sutimlimab for Cold Agglutinin Disease.

Mark Reid¹, Bethany A Fedutes Henderson²

¹From The James Cancer Hospital at The Ohio State University, Columbus, Ohio.

Journal of the Advanced Practitioner in Oncology

|September 27, 2024

Summary

Cold agglutinin disease (CAD) is a rare autoimmune anemia. Sutimlimab, a C1s inhibitor, effectively treats CAD by improving hemoglobin, reducing hemolysis, and alleviating fatigue in patients.

Area of Science:

Hematology
Immunology
Pharmacology

Background:

Cold agglutinin disease (CAD) is a rare autoimmune hemolytic anemia distinct from warm antibody AIHA.
CAD is characterized by complement-mediated hemolysis and is often unresponsive to corticosteroids.
Therapeutic options for CAD have historically included immunotherapy with variable responses, and the condition carries risks of thrombosis and mortality.

Purpose of the Study:

To provide advanced practice providers (APPs) with a comprehensive overview of CAD.
To focus on sutimlimab as a novel therapeutic option for CAD.
To equip APPs with the knowledge to manage patients receiving sutimlimab therapy.

Main Methods:

Review of existing medical literature on CAD and sutimlimab.

More Related Videos

Single-cell Analysis of Immunophenotype and Cytokine Production in Peripheral Whole Blood via Mass Cytometry

Single-cell Analysis of Immunophenotype and Cytokine Production in Peripheral Whole Blood via Mass Cytometry

Published on: June 26, 2018

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

Related Experiment Videos

Last Updated: Jul 17, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Single-cell Analysis of Immunophenotype and Cytokine Production in Peripheral Whole Blood via Mass Cytometry

Single-cell Analysis of Immunophenotype and Cytokine Production in Peripheral Whole Blood via Mass Cytometry

Published on: June 26, 2018

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

Analysis of Phase III clinical trial data for sutimlimab in CAD patients.

Synthesis of information relevant to APP practice in managing CAD.

Main Results:

Sutimlimab, a C1s inhibitor, demonstrated efficacy in two Phase III studies for CAD treatment.
Sutimlimab improved key indicators including hemoglobin levels and hemolysis.
Patients treated with sutimlimab experienced significant improvement in fatigue.

Conclusions:

Sutimlimab represents a critical therapeutic advancement for cold agglutinin disease.
Complement inhibition, specifically targeting C1s, is a viable strategy for CAD.
This article serves as a vital resource for APPs managing CAD patients on sutimlimab.